CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients
Xiaotao Qian(Nanfang Hospital), Changxuan You(Southern Medical University), Tao Sun(University of Bonn), Jing Wang(Peking University), Yuan He(Xuzhou Medical College), Weihai Xing(Fuyang City People's Hospital), Zhiyong Yang(Wuhan University), Xuekun Song(Henan University of Traditional Chinese Medicine)
Cited by 126
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
ALKBH5 Inhibits Pancreatic Cancer Motility by Decreasing Long Non-Coding RNA KCNK15-AS1 Methylation
|Cellular Physiology and Biochemistry|2018|294